Alzheimer’s drugs targeting amyloid do not produce clinically meaningful effects, concludes Cochrane review

Alzheimer’s drugs targeting amyloid β proteins “do not produce clinically meaningful positive effects” and slightly increase the risk of swelling and bleeding in the brain, an independent Cochrane review has concluded.1